The latest from across eye care — curated by B-Seen
Large language models (LLMs) now assist with drafting, translation, literature searches, and peer-review preparation. Such use is not inherently problematic: Supervised assistance can improve clarity and reduce language barriers. The concern is that undisclosed assistance obscures how a scientific text was produced and who is accountable for it.
Infection with varicella zoster virus (VZV) causes the exanthem varicella, as well as establishing a life-long latent VZV infection of primary sensory neurons. Reactivation of this latent infection may cause classic dermatomal zoster, limited dermatomal zoster, disease without skin eruption, or even viral shedding in the absence of clinical disease, including viremia in otherwise healthy individuals. Recurrent zoster is not uncommon, with a 10-year cumulative risk of 9.9% for recurrent dermatomal zoster in patients who are immunocompetent and unvaccinated1 and a 6.3-year cumulative risk of 23% for recurrent VZV of the eye or globe after an initial episode of ophthalmic zoster with a classic rash in the V1 dermatome.
Pupil dilation could skew IOL power calculations by increasing anterior chamber depth and reducing lens thickness, according to a study published in Journal of Refractive Surgery. “Because biometry and IOL power calculations are commonly performed on the same day once a decision for surgery has been made, biometry is usually performed while the patient’s pupils are still dilated,” David Z. Chen, MBBS, FRCOphth, of National University Hospital in Singapore, and colleagues wrote. “Currently, there is no consensus on how mydriatics influence biometric results and, if so, which parameters are
NEW YORK—Hubble, a vision care company committed to making contact lenses more accessible and affordable through its direct-to-consumer platform, has announced the appointment of Jeff Berger as chief executive officer. Berger will lead Hubble's strategic vision, operations, and continued expansion as the company builds on its position at the intersection of vision care, consumer products, and subscription commerce, the announcement noted. As CEO, Berger will focus on accelerating product innovation, strengthening relationships with eyecare professionals, expanding Hubble's portfolio, and making high-quality vision care more accessible to consumers, the announcement said. Berger took over as CEO in early June, replacing Steve Druckman, Hubble told VMAIL.
MIAMI— Avulux, the manufacturer of clinically-proven precision light-filtering lenses for people living with migraine and light sensitivity, has announced that the U.S. Food and Drug Administration (FDA) has granted the company De Novo marketing authorization—which is used for new, first-of-their-kind types of medical devices—establishing the first FDA-recognized category for a precision optical filter designed to help manage light sensitivity associated with migraine. The authorization gives Avulux a defined regulatory pathway as a first-of-its-kind medical device, one the company said provides patients and clinicians with a clearer way to understand its intended use.
MIAMI—Innovative Eyewear, Inc. (NASDAQ: LUCYW), the developer and manufacturer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands, has announced a new strategic alliance with a HTC Corporation, a well-known electronics manufacturer of Taiwan. The alliance is centered on the U.S. commercialization of the Vive Eagle smart eyewear line, which Innovative Eyewear plans to make available on its flagship Lucyd.co smart eyewear web store in September 2026, the announcement stated.
ALEXANDRIA, Va.—The Vision Council Foundation has kicked off its 2026 back-to-school eye health campaign titled See What Matters – Empowering Education, encouraging families to prioritize comprehensive eye exams and healthy vision habits as students return to the classroom. The foundation said this year's campaign places special emphasis on behaviors and conditions that can impede learning, including digital eye strain and dry eye from screen use, as well as the prevalence of childhood myopia, which affects roughly 30 percent of children and adolescents in the U.S. today.
IRVING, Texas—Review of Myopia Management (RMM) has announced a live, full-day event on August 30, 2026, at the OMNI Las Colinas Hotel, Irving, Texas, designed to help ECPs implement or strengthen their myopia management programs.
The Canadian Association of Optometrists (CAO) is launching a new digital awareness campaign urging parents to prioritize regular comprehensive eye exams for their children. Eye exams play a critical role in ensuring every child is set up for success in the classroom, yet eye health often receives less attention than other routine health care.
Mix-and-match IOL strategies can improve visual acuity and quality as effectively as bilateral multifocal IOL implantation, according to a study in Journal of Refractive Surgery. “Although bilateral implantation of multifocal IOLs remains a standard approach that provides full-range vision and spectacle independence, the mix-and-match strategy offers solutions for patients with asymmetric ocular conditions or specific visual demands,” Lan Wang, MD, of Eye & ENT Hospital, Fudan University, and colleagues wrote. To assess the efficacy of mix-and-match IOL strategies in patients undergoing
More than 39,000 bottles of Clear Eyes Maximum itchy eye relief may potentially be contaminated and are being recalled, according to the FDA. A total of 39,060 15 mL bottles of the eye drops, which expire on Sept. 30, 2027, were recalled by Prestige Consumer Healthcare due to a “lack of assurance of sterility” and “potential contamination.” Contamination was not confirmed, but the company determined that one lot had “potential for contamination” and voluntarily initiated a recall, Phil Terpolilli, CFA, vice president of investor relations, treasury and
KIAWAH ISLAND, S.C. — A thorough workup should be conducted when determining the cause of bilateral eyelid swelling, according to a speaker at Kiawah Eye & Retina. “The differential diagnosis for bilateral lid swelling is incredibly large,” Susannah L. Brown, MD, said during a presentation. “It could be ... infectious, inflammation, allergic, neoplastic, traumatic or age-related.” Common causes of bilateral eyelid swelling include bilateral preseptal cellulitis, bilateral dacryocystitis, inflammatory disease, thyroid eye disease, blepharitis or angioedema, Brown said in the presentation.
NEWARK, N.J.—Healthcare practices, including optometry offices, are increasingly open to artificial intelligence (AI) as a way to improve operations, but new survey data suggest adoption remains in an early stage as concerns about privacy, quality and workflow integration continue to slow broader use. In a multidisciplinary survey of 285 healthcare practice owners, office managers and front desk staff across dental, specialty medical, optometry and veterinary practices conducted by Weave, 41 percent of respondents said they have already adopted some AI workflows or believe AI is transforming operations, while another 33 percent said they have considered AI tools but have not yet committed.
NEWARK, N.J. and LOS ANGELES—In June, newly established independent eyewear company Cardine announced its official debut into the optical industry. Cardine was founded in 2025 by Tatiana De Arruda, an accomplished creative director who has held leadership roles at Marchon, Safilo and De Rigo and has designed for fashion houses including Bottega Veneta, Marc Jacobs and Calvin Klein; and Noel and Javan Diaz, the father-and-son team behind the Santa Clarita, Calif.-based optical laboratory Simplify Optics. Cardine marks Noel and Javan’s first venture into the eyewear category; together, they have more than a century of combined optical lens expertise and a reputation for precision-crafted, locally produced work.
DALLAS—The Optical Women’s Association (OWA) has announced the launch of START STRONG. Powered by the OWA, a global connection event taking place at Silmo Paris on Saturday, September 26, at 8:30 a.m. CEST. In an announcement, the OWA said this launch constitutes a significant milestone in its international expansion journey. “As the OWA continues to expand its mission beyond North America, this event marks an important step in building a truly global community of optical professionals committed to connection, leadership, mentorship and advancing opportunities for women across the industry,” the association said.
VAUGHAN, Ontario.—Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, has announced changes to its board of directors and reaffirmed its 2026 full-year guidance, which it raised on July 29, 2026. Effective Aug. 5, 2026, the Bausch + Lomb board of directors appointed four new directors: Thomas J. Appio, Robert Chersi, Laurence Paul, MD, and Barbara Trebbi.
Creating a medication tailored to the needs of an individual patient. FDA answers the “what” and “why” of compounding. From consumers to health care professionals, there are many questions about compounding. FDA works to answer questions related to the meaning, intent and requirements of compounding
The FDA is seeking feedback on a potential way of regulating medical devices equipped with generative AI features, informed by the process of training human clinicians. Described as a “competency-based approach,” the process would evaluate AI-equipped devices in increasingly clinical scenarios, including potentially with real patients. It is “inspired, at a high level, by how human clinicians are evaluated and credentialed,” according to an FDA discussion paper. The paper also discussed ongoing evaluation of AI devices after they come to market, noting that the FDA is “considering whether it is
A 34-year-old woman presented with 2 weeks of a deep, dull ache behind her left eye accompanied by redness and light sensitivity. The pain was constant, worse with eye movement and not associated with any change in vision at onset. She was evaluated by an ophthalmologist who noted scleral injection and started naproxen 500 mg twice daily. Her pain partially improved on this regimen; however, over the ensuing days, her vision became progressively blurry and cloudy in the left eye, prompting an urgent return approximately 2 weeks after symptom onset. She denied significant discharge, double
Performing cataract surgery in eyes with high degrees of hyperopia can give great refractive results, but there are challenges to overcome. Eyes with short axial lengths typically have a shallow anterior chamber, a disproportionately large crystalline lens and elevated posterior vitreous pressure, all of which create a crowded space in which every surgical maneuver must be deliberate. Operating successfully in these short eyes requires a refined approach spanning preoperative evaluation, specialized biometry, modified fluidics and careful patient counseling regarding postoperative optics. At
DALLAS—The Optical Women’s Association (OWA) has announced the launch of START STRONG. Powered by the OWA, a global connection event taking place at Silmo Paris on Saturday, September 26, at 8:30 a.m. CEST. In an announcement, the OWA said this launch constitutes a significant milestone in its international expansion journey.
MUMBAI; NAPLES, Fla.; WARREN, N.J.; AMSTERDAM; LONDON—Global pharma company Lupin Limited (Bloomberg: LPCIN) has announced that VISUfarma B.V., a wholly owned subsidiary of Lupin, has inked an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited, granting VISUfarma the exclusive rights to commercialize, market, promote, distribute, and sell Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% within the European Union, the U.K., Switzerland, Norway and Iceland. A once-daily, dual-agent eye drop, Yuvezzi is indicated for the treatment of presbyopia in adults.
There are several advantages of a systematic review or meta-analysis worth mentioning. In addition to a meticulous review of the current literature, by combining data from selected studies that meet prespecified inclusion criteria, meta-analysis relying on a larger sample size offers greater statistical power than an individual study, thereby providing the best evidence.1,2
A profound awareness surrounding the myopia crisis is front and center for eye care providers around the globe. Initially projected rising prevalence figures will likely be shattered as significant, unexpected increases in myopia incidence after the coronavirus disease 2019 pandemic have been observed, particularly in East Asia, possibly due to strict regulations requiring children to stay indoors and receive remote education. However, the role of the visual environment on the development and/or progression of myopia remains elusive, fueling the National Academies of Sciences, Engineering, and Medicine to form a myopia focus committee and call on “eye care professionals, federal agencies, and funding agencies to make improvements to standardize care, increase funding to study treatments, encourage outdoor time, and overall facilitate the standardization of assessments and diagnostics.”
New law strengthens transparency, protects patient and provider choice and expands accountability for vision benefit middlemen, building on 2023’s Vision Care Plan Regulation Act.
After decades of modest innovation, the options for glaucoma surgery have grown at a rapid pace. This expansion of the glaucoma surgical armamentarium hides an uncomfortable truth: we have so many surgical options because none deliver consistent results across the broad range of presenting clinical scenarios. The ultimate innovation would be a surgery that achieves excellent intraocular pressure (IOP) lowering, with highly consistent results and a low risk profile. This goal was artfully phrased as “10-10-10” by Professor Peng Khaw of Moorfields Eye Hospital, who framed the ideal surgical intervention as one that would reduce IOP to 10 mmHg in a 10-minute procedure that lasts 10 years.
PHOENIX — The odds of cognitive impairment in nursing homes increase with the severity of visual impairment, according to data presented at Optometry’s Meeting. Researchers from the University of South Florida conducted a cross-sectional analysis of 9,935 nursing home residents aged 65 years and older who were included in the Western North Carolina Nursing Home Study. Based on logMAR visual acuity, residents were categorized as having normal vision, mild or moderate visual impairment, or blindness. The researchers used a large language model to extract information about their diagnoses and
KIAWAH ISLAND, S.C. — Surgeons who perform corneal allogenic intrastromal ring segment procedures should keep planning simple, according to a speaker at Kiawah Eye & Retina. In a presentation, Neel R. Desai, MD, shared pearls and what he wished he knew before he started using corneal allogenic intrastromal ring segments (CAIRS) in patients with keratoconus, specifically when placing the ring segments using manual dissection. “When you conceptually think about dissecting or cross planes with a femtosecond laser, it is indiscriminate with respect to the femtosecond laser plane being a fixed
BOSTON and SAN FRANCISCO—Eyebot, a developer of automated vision testing kiosks that provides doctor-verified eyeglass prescriptions, today announced a strategic partnership with Quay, the global eyewear brand known for on-trend design and premium materials. Through this partnership, Eyebot’s automated vision test kiosks are now available inside select Quay retail stores, allowing customers to receive a prescription while shopping for new glasses, the companies said. The initial rollout includes Quay’s Irvine Spectrum and Victoria Gardens locations in Southern California, with more locations on the way, and will allow Quay and Eyebot to introduce the service to customers in-store while exploring opportunities to expand access across Quay’s retail footprint.
NEWARK, N.J. and LOS ANGELES—In June, newly established independent eyewear company Cardine announced its official debut into the optical industry. Cardine was founded in 2025 by Tatiana De Arruda, an accomplished creative director who has held leadership roles at Marchon, Safilo and De Rigo and has designed for fashion houses including Bottega Veneta, Marc Jacobs and Calvin Klein; and Noel and Javan Diaz, the father-and-son team behind the Santa Clarita, Calif.-based optical laboratory Simplify Optics. Cardine marks Noel and Javan’s first venture into the eyewear category; together, they have more than a century of combined optical lens expertise and a reputation for precision-crafted, locally produced work.
NEWARK, N.J. and LOS ANGELES—In June, newly established independent eyewear company Cardine announced its official debut into the optical industry. Cardine was founded in 2025 by Tatiana De Arruda, an accomplished creative director who has held leadership roles at Marchon, Safilo and De Rigo and has designed for fashion houses including Bottega Veneta, Marc Jacobs and Calvin Klein; and Noel and Javan Diaz, the father-and-son team behind the Santa Clarita, Calif.-based optical laboratory Simplify Optics. Cardine marks Noel and Javan’s first venture into the eyewear category; together, they have more than a century of combined optical lens expertise and a reputation for precision-crafted, locally produced work.
IRVINE, Calif.—SDC Technologies, a global leader in the development and manufacturing of high-performance specialty coatings, has announced a significant follow-on investment in flō Optics, a pioneer in digital lens coating and surface treatment technologies, as part of its recently completed SAFE (Simple Agreement for Future Equity) financing round. As a lead strategic investor in the round, SDC Technologies, a wholly owned subsidiary of Mitsui Chemicals, Inc., said it has “significantly expanded its investment, reinforcing its commitment to flō Optics and its innovative digital coating platform,” and will appoint a representative to flō Optics’ board of directors, further strengthening the strategic collaboration between the two companies.
JENA, Germany—Zeiss Medical Technology, a leading global medical technology company, has announced 510k clearance from the U.S. Food and Drug Administration for Zeiss Clinic 360. An all-in-one cloud and browser-based software product, Zeiss Clinic 360 combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression, support treatment decisions, and improve workflow efficiency. It is part of the Zeiss ophthalmic workflow portfolio and will be available in the U.S. in early fall 2026, the company advised.
BOSTON—Ora, a global ophthalmic contract research organization (CRO), has appointed João (John) Trein, MD, MPH, as therapeutic lead, posterior, further strengthening the company's leadership in retinal disease and posterior segment drug development, according to an announcement from Ora. A fellowship-trained ophthalmologist and practicing retina specialist, Dr. Trein brings more than 20 years of clinical, surgical and research experience in retinal diseases, along with extensive expertise in ophthalmic drug development and global clinical trials. In his new role, Dr. Trein will provide strategic scientific and clinical leadership across the company’s posterior segment programs, helping innovators optimize study design, endpoint strategy, patient identification, safety oversight and program execution, Ora noted.
MENLO PARK, Calif.—Eyecare tech company Sight Sciences, Inc. (Nasdaq: SGHT) announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the indications for use for its TearCare System, allowing it to be used for improving meibomian gland function in adult patients with evaporative dry eye disease resulting from meibomian gland dysfunction (MGD). As a result of this expanded indication, TearCare is now the first and only treatment for MGD indicated to improve meibomian gland function in patients suffering from dry eye disease, the company said.
Recent studies have shown a connection between the gut microbiome, a community of microorganisms, and specific eye conditions, such as ocular surface diseases, retinal disorders, and immune-mediated eye diseases. Gut microbes may influence these conditions by regulating the immune system or altering metabolites. They play a crucial role in maintaining the integrity of the intestinal barrier, influencing host nutrient metabolism, participating in immune regulation, and combating pathogens. Reduced variety and balance in the gut microbiome can pave the way for one type of microorganism to take over, making us more vulnerable to inflammation and infections from germs living inside and outside of our bodies. (Zhao Y, Qiu P, Shen T. Gut microbiota and eye diseases: A review. Medicine (Baltimore). 2024 Sep 27;103(39):e39866. doi: 10.1097/MD.0000000000039866. PMID: 39331938; PMCID: PMC11441905)
Understanding the inflection point marking the onset of diabetic retinal disease (DRD) and the risk factors associated with it remains of preeminent importance. In this issue, Sampani et al1 (p. xxx) report findings from a cohort of 1359 young patients with type 1 diabetes mellitus (T1DM) at a large tertiary referral center between 2005 and 2020. A subset of these patients—69 individuals, covering 133 eyes—also underwent spectral domain-OCT imaging. In their analysis, they found that 5.1% (131 eyes) had DRD, and a small fraction (0.3% or 9 eyes) had diabetic macular edema.
The introduction of tumor necrosis factor (TNF)-α inhibitors has successfully transformed the management of noninfectious uveitis over the past 2 decades. The Adalimumab in active and inactive non-infectious uveitis (VISUAL) trials established adalimumab as the first and currently only anti-TNF therapy approved for noninfectious intermediate uveitis, posterior uveitis, and panuveitis, demonstrating effective corticosteroid-sparing disease control in both active and inactive disease.1,2 Subsequent studies have served to refine our understanding of the role of adalimumab in uveitis management.
The FDA granted 510(k) clearance to Zeiss Clinic 360, a cloud-based tool for managing and tracking patient data in eye care, according to Zeiss. The software is expected to be available in the U.S. in the early fall through a subscription. Zeiss Clinic 360 works in a web browser and aims to give a “comprehensive patient view” by bringing together data from diagnostic devices, electronic medical records and other practice systems, according to the company. It analyzes trends in clinical data and can be used to track progression of glaucoma and other diseases. “Clinic 360 is designed to be vendor
CMS has updated its guidance on prior authorization metrics reporting, addressing the AMA’s concerns about how health insurers were disclosing requirements and outcomes, according to the organization. The AMA said it notified CMS about issues with reporting metrics after it conducted a review examining how 15 Medicare Advantage contracts were abiding by the transparency requirements from CMS’s 2024 Interoperability and Prior Authorization final rule. The review showed that “on the surface, many plans appeared to comply with the rule while presenting disclosures in places and formats that made
Tarsus Pharmaceuticals is entering the retina space with deals to acquire Alkeus Pharmaceuticals and iRenix Medical, according to press releases. The acquisitions are focused on two therapies: gildeuretinol (ALK-001, Alkeus Pharmaceuticals) and IRX-101 (iRenix Medical). Gildeuretinol is an investigational once-daily oral therapy for the treatment of Stargardt disease designed to reduce damage to the retina caused by the accumulation of toxic dimers, while IRX-101 is an investigational ocular antiseptic designed to reduce pain and corneal toxicity after intravitreal injections, according to
The World Council of Optometry (WCO) and Alcon are expanding their global dry eye education initiative through a new partnership with the International Association of Contact Lens Educators (IACLE). This collaboration will allow university instructors worldwide to easily access the program’s digital learning tools directly through the IACLE Teaching Online Platform (IACLETOP).
Large language models (LLMs) now assist with drafting, translation, literature searches, and peer-review preparation. Such use is not inherently problematic: Supervised assistance can improve clarity and reduce language barriers. The concern is that undisclosed assistance obscures how a scientific text was produced and who is accountable for it.
Infection with varicella zoster virus (VZV) causes the exanthem varicella, as well as establishing a life-long latent VZV infection of primary sensory neurons. Reactivation of this latent infection may cause classic dermatomal zoster, limited dermatomal zoster, disease without skin eruption, or even viral shedding in the absence of clinical disease, including viremia in otherwise healthy individuals. Recurrent zoster is not uncommon, with a 10-year cumulative risk of 9.9% for recurrent dermatomal zoster in patients who are immunocompetent and unvaccinated1 and a 6.3-year cumulative risk of 23% for recurrent VZV of the eye or globe after an initial episode of ophthalmic zoster with a classic rash in the V1 dermatome.
Pupil dilation could skew IOL power calculations by increasing anterior chamber depth and reducing lens thickness, according to a study published in Journal of Refractive Surgery. “Because biometry and IOL power calculations are commonly performed on the same day once a decision for surgery has been made, biometry is usually performed while the patient’s pupils are still dilated,” David Z. Chen, MBBS, FRCOphth, of National University Hospital in Singapore, and colleagues wrote. “Currently, there is no consensus on how mydriatics influence biometric results and, if so, which parameters are
NEW YORK—Hubble, a vision care company committed to making contact lenses more accessible and affordable through its direct-to-consumer platform, has announced the appointment of Jeff Berger as chief executive officer. Berger will lead Hubble's strategic vision, operations, and continued expansion as the company builds on its position at the intersection of vision care, consumer products, and subscription commerce, the announcement noted. As CEO, Berger will focus on accelerating product innovation, strengthening relationships with eyecare professionals, expanding Hubble's portfolio, and making high-quality vision care more accessible to consumers, the announcement said. Berger took over as CEO in early June, replacing Steve Druckman, Hubble told VMAIL.
MIAMI— Avulux, the manufacturer of clinically-proven precision light-filtering lenses for people living with migraine and light sensitivity, has announced that the U.S. Food and Drug Administration (FDA) has granted the company De Novo marketing authorization—which is used for new, first-of-their-kind types of medical devices—establishing the first FDA-recognized category for a precision optical filter designed to help manage light sensitivity associated with migraine. The authorization gives Avulux a defined regulatory pathway as a first-of-its-kind medical device, one the company said provides patients and clinicians with a clearer way to understand its intended use.
MIAMI—Innovative Eyewear, Inc. (NASDAQ: LUCYW), the developer and manufacturer of smart eyewear under the Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands, has announced a new strategic alliance with a HTC Corporation, a well-known electronics manufacturer of Taiwan. The alliance is centered on the U.S. commercialization of the Vive Eagle smart eyewear line, which Innovative Eyewear plans to make available on its flagship Lucyd.co smart eyewear web store in September 2026, the announcement stated.
ALEXANDRIA, Va.—The Vision Council Foundation has kicked off its 2026 back-to-school eye health campaign titled See What Matters – Empowering Education, encouraging families to prioritize comprehensive eye exams and healthy vision habits as students return to the classroom. The foundation said this year's campaign places special emphasis on behaviors and conditions that can impede learning, including digital eye strain and dry eye from screen use, as well as the prevalence of childhood myopia, which affects roughly 30 percent of children and adolescents in the U.S. today.
IRVING, Texas—Review of Myopia Management (RMM) has announced a live, full-day event on August 30, 2026, at the OMNI Las Colinas Hotel, Irving, Texas, designed to help ECPs implement or strengthen their myopia management programs.
The Canadian Association of Optometrists (CAO) is launching a new digital awareness campaign urging parents to prioritize regular comprehensive eye exams for their children. Eye exams play a critical role in ensuring every child is set up for success in the classroom, yet eye health often receives less attention than other routine health care.
Mix-and-match IOL strategies can improve visual acuity and quality as effectively as bilateral multifocal IOL implantation, according to a study in Journal of Refractive Surgery. “Although bilateral implantation of multifocal IOLs remains a standard approach that provides full-range vision and spectacle independence, the mix-and-match strategy offers solutions for patients with asymmetric ocular conditions or specific visual demands,” Lan Wang, MD, of Eye & ENT Hospital, Fudan University, and colleagues wrote. To assess the efficacy of mix-and-match IOL strategies in patients undergoing
More than 39,000 bottles of Clear Eyes Maximum itchy eye relief may potentially be contaminated and are being recalled, according to the FDA. A total of 39,060 15 mL bottles of the eye drops, which expire on Sept. 30, 2027, were recalled by Prestige Consumer Healthcare due to a “lack of assurance of sterility” and “potential contamination.” Contamination was not confirmed, but the company determined that one lot had “potential for contamination” and voluntarily initiated a recall, Phil Terpolilli, CFA, vice president of investor relations, treasury and
KIAWAH ISLAND, S.C. — A thorough workup should be conducted when determining the cause of bilateral eyelid swelling, according to a speaker at Kiawah Eye & Retina. “The differential diagnosis for bilateral lid swelling is incredibly large,” Susannah L. Brown, MD, said during a presentation. “It could be ... infectious, inflammation, allergic, neoplastic, traumatic or age-related.” Common causes of bilateral eyelid swelling include bilateral preseptal cellulitis, bilateral dacryocystitis, inflammatory disease, thyroid eye disease, blepharitis or angioedema, Brown said in the presentation.
NEWARK, N.J.—Healthcare practices, including optometry offices, are increasingly open to artificial intelligence (AI) as a way to improve operations, but new survey data suggest adoption remains in an early stage as concerns about privacy, quality and workflow integration continue to slow broader use. In a multidisciplinary survey of 285 healthcare practice owners, office managers and front desk staff across dental, specialty medical, optometry and veterinary practices conducted by Weave, 41 percent of respondents said they have already adopted some AI workflows or believe AI is transforming operations, while another 33 percent said they have considered AI tools but have not yet committed.
NEWARK, N.J. and LOS ANGELES—In June, newly established independent eyewear company Cardine announced its official debut into the optical industry. Cardine was founded in 2025 by Tatiana De Arruda, an accomplished creative director who has held leadership roles at Marchon, Safilo and De Rigo and has designed for fashion houses including Bottega Veneta, Marc Jacobs and Calvin Klein; and Noel and Javan Diaz, the father-and-son team behind the Santa Clarita, Calif.-based optical laboratory Simplify Optics. Cardine marks Noel and Javan’s first venture into the eyewear category; together, they have more than a century of combined optical lens expertise and a reputation for precision-crafted, locally produced work.
DALLAS—The Optical Women’s Association (OWA) has announced the launch of START STRONG. Powered by the OWA, a global connection event taking place at Silmo Paris on Saturday, September 26, at 8:30 a.m. CEST. In an announcement, the OWA said this launch constitutes a significant milestone in its international expansion journey. “As the OWA continues to expand its mission beyond North America, this event marks an important step in building a truly global community of optical professionals committed to connection, leadership, mentorship and advancing opportunities for women across the industry,” the association said.
VAUGHAN, Ontario.—Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, has announced changes to its board of directors and reaffirmed its 2026 full-year guidance, which it raised on July 29, 2026. Effective Aug. 5, 2026, the Bausch + Lomb board of directors appointed four new directors: Thomas J. Appio, Robert Chersi, Laurence Paul, MD, and Barbara Trebbi.
Creating a medication tailored to the needs of an individual patient. FDA answers the “what” and “why” of compounding. From consumers to health care professionals, there are many questions about compounding. FDA works to answer questions related to the meaning, intent and requirements of compounding
The FDA is seeking feedback on a potential way of regulating medical devices equipped with generative AI features, informed by the process of training human clinicians. Described as a “competency-based approach,” the process would evaluate AI-equipped devices in increasingly clinical scenarios, including potentially with real patients. It is “inspired, at a high level, by how human clinicians are evaluated and credentialed,” according to an FDA discussion paper. The paper also discussed ongoing evaluation of AI devices after they come to market, noting that the FDA is “considering whether it is
A 34-year-old woman presented with 2 weeks of a deep, dull ache behind her left eye accompanied by redness and light sensitivity. The pain was constant, worse with eye movement and not associated with any change in vision at onset. She was evaluated by an ophthalmologist who noted scleral injection and started naproxen 500 mg twice daily. Her pain partially improved on this regimen; however, over the ensuing days, her vision became progressively blurry and cloudy in the left eye, prompting an urgent return approximately 2 weeks after symptom onset. She denied significant discharge, double
Performing cataract surgery in eyes with high degrees of hyperopia can give great refractive results, but there are challenges to overcome. Eyes with short axial lengths typically have a shallow anterior chamber, a disproportionately large crystalline lens and elevated posterior vitreous pressure, all of which create a crowded space in which every surgical maneuver must be deliberate. Operating successfully in these short eyes requires a refined approach spanning preoperative evaluation, specialized biometry, modified fluidics and careful patient counseling regarding postoperative optics. At
DALLAS—The Optical Women’s Association (OWA) has announced the launch of START STRONG. Powered by the OWA, a global connection event taking place at Silmo Paris on Saturday, September 26, at 8:30 a.m. CEST. In an announcement, the OWA said this launch constitutes a significant milestone in its international expansion journey.
MUMBAI; NAPLES, Fla.; WARREN, N.J.; AMSTERDAM; LONDON—Global pharma company Lupin Limited (Bloomberg: LPCIN) has announced that VISUfarma B.V., a wholly owned subsidiary of Lupin, has inked an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited, granting VISUfarma the exclusive rights to commercialize, market, promote, distribute, and sell Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% within the European Union, the U.K., Switzerland, Norway and Iceland. A once-daily, dual-agent eye drop, Yuvezzi is indicated for the treatment of presbyopia in adults.
There are several advantages of a systematic review or meta-analysis worth mentioning. In addition to a meticulous review of the current literature, by combining data from selected studies that meet prespecified inclusion criteria, meta-analysis relying on a larger sample size offers greater statistical power than an individual study, thereby providing the best evidence.1,2
A profound awareness surrounding the myopia crisis is front and center for eye care providers around the globe. Initially projected rising prevalence figures will likely be shattered as significant, unexpected increases in myopia incidence after the coronavirus disease 2019 pandemic have been observed, particularly in East Asia, possibly due to strict regulations requiring children to stay indoors and receive remote education. However, the role of the visual environment on the development and/or progression of myopia remains elusive, fueling the National Academies of Sciences, Engineering, and Medicine to form a myopia focus committee and call on “eye care professionals, federal agencies, and funding agencies to make improvements to standardize care, increase funding to study treatments, encourage outdoor time, and overall facilitate the standardization of assessments and diagnostics.”
New law strengthens transparency, protects patient and provider choice and expands accountability for vision benefit middlemen, building on 2023’s Vision Care Plan Regulation Act.
After decades of modest innovation, the options for glaucoma surgery have grown at a rapid pace. This expansion of the glaucoma surgical armamentarium hides an uncomfortable truth: we have so many surgical options because none deliver consistent results across the broad range of presenting clinical scenarios. The ultimate innovation would be a surgery that achieves excellent intraocular pressure (IOP) lowering, with highly consistent results and a low risk profile. This goal was artfully phrased as “10-10-10” by Professor Peng Khaw of Moorfields Eye Hospital, who framed the ideal surgical intervention as one that would reduce IOP to 10 mmHg in a 10-minute procedure that lasts 10 years.
PHOENIX — The odds of cognitive impairment in nursing homes increase with the severity of visual impairment, according to data presented at Optometry’s Meeting. Researchers from the University of South Florida conducted a cross-sectional analysis of 9,935 nursing home residents aged 65 years and older who were included in the Western North Carolina Nursing Home Study. Based on logMAR visual acuity, residents were categorized as having normal vision, mild or moderate visual impairment, or blindness. The researchers used a large language model to extract information about their diagnoses and
KIAWAH ISLAND, S.C. — Surgeons who perform corneal allogenic intrastromal ring segment procedures should keep planning simple, according to a speaker at Kiawah Eye & Retina. In a presentation, Neel R. Desai, MD, shared pearls and what he wished he knew before he started using corneal allogenic intrastromal ring segments (CAIRS) in patients with keratoconus, specifically when placing the ring segments using manual dissection. “When you conceptually think about dissecting or cross planes with a femtosecond laser, it is indiscriminate with respect to the femtosecond laser plane being a fixed
BOSTON and SAN FRANCISCO—Eyebot, a developer of automated vision testing kiosks that provides doctor-verified eyeglass prescriptions, today announced a strategic partnership with Quay, the global eyewear brand known for on-trend design and premium materials. Through this partnership, Eyebot’s automated vision test kiosks are now available inside select Quay retail stores, allowing customers to receive a prescription while shopping for new glasses, the companies said. The initial rollout includes Quay’s Irvine Spectrum and Victoria Gardens locations in Southern California, with more locations on the way, and will allow Quay and Eyebot to introduce the service to customers in-store while exploring opportunities to expand access across Quay’s retail footprint.
NEWARK, N.J. and LOS ANGELES—In June, newly established independent eyewear company Cardine announced its official debut into the optical industry. Cardine was founded in 2025 by Tatiana De Arruda, an accomplished creative director who has held leadership roles at Marchon, Safilo and De Rigo and has designed for fashion houses including Bottega Veneta, Marc Jacobs and Calvin Klein; and Noel and Javan Diaz, the father-and-son team behind the Santa Clarita, Calif.-based optical laboratory Simplify Optics. Cardine marks Noel and Javan’s first venture into the eyewear category; together, they have more than a century of combined optical lens expertise and a reputation for precision-crafted, locally produced work.
NEWARK, N.J. and LOS ANGELES—In June, newly established independent eyewear company Cardine announced its official debut into the optical industry. Cardine was founded in 2025 by Tatiana De Arruda, an accomplished creative director who has held leadership roles at Marchon, Safilo and De Rigo and has designed for fashion houses including Bottega Veneta, Marc Jacobs and Calvin Klein; and Noel and Javan Diaz, the father-and-son team behind the Santa Clarita, Calif.-based optical laboratory Simplify Optics. Cardine marks Noel and Javan’s first venture into the eyewear category; together, they have more than a century of combined optical lens expertise and a reputation for precision-crafted, locally produced work.
IRVINE, Calif.—SDC Technologies, a global leader in the development and manufacturing of high-performance specialty coatings, has announced a significant follow-on investment in flō Optics, a pioneer in digital lens coating and surface treatment technologies, as part of its recently completed SAFE (Simple Agreement for Future Equity) financing round. As a lead strategic investor in the round, SDC Technologies, a wholly owned subsidiary of Mitsui Chemicals, Inc., said it has “significantly expanded its investment, reinforcing its commitment to flō Optics and its innovative digital coating platform,” and will appoint a representative to flō Optics’ board of directors, further strengthening the strategic collaboration between the two companies.
JENA, Germany—Zeiss Medical Technology, a leading global medical technology company, has announced 510k clearance from the U.S. Food and Drug Administration for Zeiss Clinic 360. An all-in-one cloud and browser-based software product, Zeiss Clinic 360 combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression, support treatment decisions, and improve workflow efficiency. It is part of the Zeiss ophthalmic workflow portfolio and will be available in the U.S. in early fall 2026, the company advised.
BOSTON—Ora, a global ophthalmic contract research organization (CRO), has appointed João (John) Trein, MD, MPH, as therapeutic lead, posterior, further strengthening the company's leadership in retinal disease and posterior segment drug development, according to an announcement from Ora. A fellowship-trained ophthalmologist and practicing retina specialist, Dr. Trein brings more than 20 years of clinical, surgical and research experience in retinal diseases, along with extensive expertise in ophthalmic drug development and global clinical trials. In his new role, Dr. Trein will provide strategic scientific and clinical leadership across the company’s posterior segment programs, helping innovators optimize study design, endpoint strategy, patient identification, safety oversight and program execution, Ora noted.
MENLO PARK, Calif.—Eyecare tech company Sight Sciences, Inc. (Nasdaq: SGHT) announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the indications for use for its TearCare System, allowing it to be used for improving meibomian gland function in adult patients with evaporative dry eye disease resulting from meibomian gland dysfunction (MGD). As a result of this expanded indication, TearCare is now the first and only treatment for MGD indicated to improve meibomian gland function in patients suffering from dry eye disease, the company said.
Recent studies have shown a connection between the gut microbiome, a community of microorganisms, and specific eye conditions, such as ocular surface diseases, retinal disorders, and immune-mediated eye diseases. Gut microbes may influence these conditions by regulating the immune system or altering metabolites. They play a crucial role in maintaining the integrity of the intestinal barrier, influencing host nutrient metabolism, participating in immune regulation, and combating pathogens. Reduced variety and balance in the gut microbiome can pave the way for one type of microorganism to take over, making us more vulnerable to inflammation and infections from germs living inside and outside of our bodies. (Zhao Y, Qiu P, Shen T. Gut microbiota and eye diseases: A review. Medicine (Baltimore). 2024 Sep 27;103(39):e39866. doi: 10.1097/MD.0000000000039866. PMID: 39331938; PMCID: PMC11441905)
Understanding the inflection point marking the onset of diabetic retinal disease (DRD) and the risk factors associated with it remains of preeminent importance. In this issue, Sampani et al1 (p. xxx) report findings from a cohort of 1359 young patients with type 1 diabetes mellitus (T1DM) at a large tertiary referral center between 2005 and 2020. A subset of these patients—69 individuals, covering 133 eyes—also underwent spectral domain-OCT imaging. In their analysis, they found that 5.1% (131 eyes) had DRD, and a small fraction (0.3% or 9 eyes) had diabetic macular edema.
The introduction of tumor necrosis factor (TNF)-α inhibitors has successfully transformed the management of noninfectious uveitis over the past 2 decades. The Adalimumab in active and inactive non-infectious uveitis (VISUAL) trials established adalimumab as the first and currently only anti-TNF therapy approved for noninfectious intermediate uveitis, posterior uveitis, and panuveitis, demonstrating effective corticosteroid-sparing disease control in both active and inactive disease.1,2 Subsequent studies have served to refine our understanding of the role of adalimumab in uveitis management.
The FDA granted 510(k) clearance to Zeiss Clinic 360, a cloud-based tool for managing and tracking patient data in eye care, according to Zeiss. The software is expected to be available in the U.S. in the early fall through a subscription. Zeiss Clinic 360 works in a web browser and aims to give a “comprehensive patient view” by bringing together data from diagnostic devices, electronic medical records and other practice systems, according to the company. It analyzes trends in clinical data and can be used to track progression of glaucoma and other diseases. “Clinic 360 is designed to be vendor
CMS has updated its guidance on prior authorization metrics reporting, addressing the AMA’s concerns about how health insurers were disclosing requirements and outcomes, according to the organization. The AMA said it notified CMS about issues with reporting metrics after it conducted a review examining how 15 Medicare Advantage contracts were abiding by the transparency requirements from CMS’s 2024 Interoperability and Prior Authorization final rule. The review showed that “on the surface, many plans appeared to comply with the rule while presenting disclosures in places and formats that made
Tarsus Pharmaceuticals is entering the retina space with deals to acquire Alkeus Pharmaceuticals and iRenix Medical, according to press releases. The acquisitions are focused on two therapies: gildeuretinol (ALK-001, Alkeus Pharmaceuticals) and IRX-101 (iRenix Medical). Gildeuretinol is an investigational once-daily oral therapy for the treatment of Stargardt disease designed to reduce damage to the retina caused by the accumulation of toxic dimers, while IRX-101 is an investigational ocular antiseptic designed to reduce pain and corneal toxicity after intravitreal injections, according to
The World Council of Optometry (WCO) and Alcon are expanding their global dry eye education initiative through a new partnership with the International Association of Contact Lens Educators (IACLE). This collaboration will allow university instructors worldwide to easily access the program’s digital learning tools directly through the IACLE Teaching Online Platform (IACLETOP).
B-Seen aggregates headlines from leading eye care publications. All content belongs to its respective publishers. Want your publication featured or removed? Contact us.
